You are viewing a historical snapshot of United Kingdom (London Stock Exchange). These figures are a preview to show what TradeTidings covers. Live, continuously updated United Kingdom sentiment and stock impact is a Pro feature.
Get live United Kingdom data with ProOver the last 90 days, Pharmaceuticals & Biotech shows 12 positive, 0 neutral and 2 negative news signals across its constituents. The auto-generated sector insight (top drivers with direction + rationale) appears here once the analysis worker has processed enough items.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
How news sentiment on the Pharmaceuticals & Biotech sector has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
The most recent stories affecting Pharmaceuticals & Biotech, across all of our coverage.
GSK plans to remove billions of pounds in costs over three years and close its Stevenage research site, moving staff to Cambridge. Lower costs support margins, a positive read for the business even as job worries rise.
AstraZeneca beat half-year profit expectations and sounded confident about its drug pipeline, easing recent investor worries. The read is a direct positive for the FTSE 100's largest company.
AstraZeneca is seeking EU approval to expand the use of its respiratory treatment Trixeo Aerosphere, extending an existing drug's addressable market.
The European Union has cleared AstraZeneca's Etcamah combination therapy as a first line treatment for ER positive breast cancer, adding a new approved option to its oncology portfolio.
AstraZeneca shares fell after one of its clinical trials failed to meet its goals, a rare setback for a pipeline that has generally had a strong hit rate.
AstraZeneca has moved a step closer to EU approval of Trixeo Aerosphere for asthma, extending a drug already sold for COPD into a much larger disease category.
GSK has won US FDA approval for its Jideytro medicine, clearing the way to sell the drug in the world's largest pharmaceutical market and adding a new product to its portfolio.
AstraZeneca has won EU approval for a breast cancer treatment, adding a new revenue source in one of Europe's largest oncology markets.
AstraZeneca shares fell after a clinical trial failed to meet its goal, a rare setback for a company whose valuation rests on a strong pipeline record.
The FDA has approved a non-small cell lung cancer treatment that GSK acquired through its Nuvalent deal, giving the drugmaker its first approved medicine from that acquisition.
First regulatory win from Nuvalent acquisition demonstrates pipeline value.
Regulatory approval for Etcamah strengthens AstraZeneca's oncology franchise.
The FDA has approved GSK's Jideytro for ROS1 positive lung cancer, giving the drugmaker a new approved treatment in a genetically defined subset of the disease.
AstraZeneca has entered into a $425 million deal granting a third party royalty rights on a portion of sales from its ATTR drug programme. The arrangement demonstrates commercial validation and generates near-term cash while sharing development and commercialisation risk.
GlaxoSmithKline completes its $10.6 billion acquisition of Nuvalent, bolstering its oncology portfolio with innovative lung cancer treatments and enhancing its position in a high-growth therapeutic area.
Investment bank Jefferies has assigned a Buy rating to GlaxoSmithKline, signaling analyst confidence in the pharmaceutical company's strategic direction and valuation.
Showing 1–16 of 93
